SCHEMBL21629512

SCHEMBL21629512

CCOC(=O)C(C)(C)Oc1ccc2c(-c3ccccc3)cc(=O)oc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.65
▸ KDM4E B2RXH2 4/20 0.65
▸ HTT P42858 2/20 0.65
▸ LMNA P02545 2/20 0.65
▸ RECQL P46063 1/20 0.65
▸ HPGD P15428 9/20 0.60
▸ USP2 O75604 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ CA9 Q16790 2/20 0.56
▸ MAOB P27338 2/20 0.55
▸ ESR1 P03372 1/20 0.53
▸ MAPT P10636 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CA12 O43570 1/20 0.50
▸ ALDH2 P05091 1/20 0.50
▸ AKR1B1 P15121 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ HSD17B3 P37058 1/20 0.50
▸ SORD Q00796 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20839412 0.87 CA12 (0.53) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL30762859 0.87 CA12 (0.53) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL30056534 0.84 RAB9A (0.56) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL21629555 0.81 ALDH1A1 (0.77) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL31089529 0.81 ALDH1A1 (0.77) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL21629622 0.81 ALDH1A1 (0.83) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL21630139 0.81 ALDH1A1 (0.62) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL21648246 0.81 ALDH1A1 (0.77) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL21629584 0.80 ALDH1A1 (0.76) ALDH1A1KDM4EHTTLMNARECQL
SCHEMBL22431636 0.77 ALDH1A1 (0.50) ALDH1A1KDM4EHTTLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US claimed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US claimed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US claimed
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 — — EP disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION TFAM, POLRMT, TUFM ALDH1A1 3415/4885KDM4E 1030/4885HTT 1580/4885
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, COX4I1, UQCRC2 ALDH1A1 1344/4885KDM4E 1057/4885HTT 3091/4885
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, COX4I1, UQCRC2 ALDH1A1 1344/4885KDM4E 1057/4885HTT 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback